**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | Prime Rounds CRC  webcast | **Project Code** | PI4VGR066 |
| **Virtual Project Manager** | Meg Quick | **Clinical Program Manager** | Amy Furedy |
| **Compliance** | Briana Devaser | **Editor** | Christi Gray |

**Launch Date/Internal Launch Date:**

**January 2015**

**Project Type**

Prime Rounds webex recorded (video)

Downloadable Slides

Podcast

Other:

**Email Blast Included?**

Yes

No

**Subject Line:**

*New prIME Rounds: Metastatic Colorectal Cancer*

**Number of E-Blasts**

Only One

Two  
Other Amount:

**Cross Promotion**

Yes

No

If Yes, List Activities:

Oncology Guru

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)

Additional Emails (Supporters?):

Peg.Bollella@sanofi.com Raghu.Vishwanath@genzyme.com Michael.andria@regeneron.com Michael.wooten@regeneron.com

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By:

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

**Friendly URL:** www.primeoncology.org/primerounds\_crc

**CME?**

Yes

No

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title:**

**prIME Rounds: CRC**

Please add your content to the form below and remove any content that is irrelevant to your activity. If something gets updated, please update this document.

**\*\*\*DO NOT LIST “SEE ATTACHED DOCUMENT”.**

**This is the only copy document that should be sent to Design.\*\*\***

**Items highlighted in YELLOW should be completed by the Clinical Team**

**Items highlighted in TEAL should be determined at the Kickoff Meeting**

**In terms of LEAN, virtual products differ in that all sections should be complete prior to sending this form to Web (there is no minimum number of sections).**

1. **[Title]**

*prIME Rounds: Metastatic Colorectal Cancer*

1. **[Activity Date]**

**Release Date:**

January XX, 2015

**Expiration Date:**January XX, 2016

1. **[Activity Overview]**

This CME-certified prIME Rounds Webcast focuses on optimal treatment selection and sequence for patients with progressive metastatic colorectal cancer.

1. **[Target Audience]**

This educational activity is specifically designed for medical oncologists, surgical and radiation oncologists, and other healthcare professionals interested and/or involved in the treatment of patients with colorectal cancer (CRC).

1. **[Learning Objectives]**

After completion of this educational activity, participants should be able to:

* Evaluate emerging clinical trial data in metastatic colorectal cancer (mCRC), including studies focused on the safety and efficacy of novel targeted therapies
* Identify strategies to individualize treatment selection and sequencing for patients with mCRC based on mutation testing, extent of metastatic disease, and other patient and disease characteristics
* Describe best practices for monitoring and managing treatment-associated adverse events in patients with mCRC to improve patient care

1. **[Faculty Listing/Featured Experts/Discussants….Faculty Listing and Featured Experts sections are stacked, Discussants section is in-line]**

Christopher Lieu, MD

University of Colorado

Aurora, Colorado, United States

Edith Mitchell, MD, FACP

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

1. **[Featured Abstracts/Discussion Topics/Activity Topics]**

**Introduction and overview**

***Christopher Lieu, MD***

**Case #1**

***Edith Mitchell, MD, FACP***

**Case #2**

***Christopher Lieu, MD***

1. **Provider**

This activity is provided by prIME Oncology.

1. **[Continuing Education]**

**US CME**

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.



prIME Oncology designates this enduring activity for a maximum of *X AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Method of Participation**

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the [Terms of Use.](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx) [[link to our Terms page]]

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with XX% or higher.

1. **Support Statement [ACCME—consult Cindy for proper verbiage and defer to BD for final approval of complete verbiage]**

This educational activity is supported by grants from Regeneron Pharmaceuticals and Sanofi.

1. **[Disclosures]**

**CME**

**Disclosure of Relevant Financial Relationships**

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Lieu has disclosed that he has received consulting fees from Sanofi-Aventis. He has agreed to represent that the information provided is complete and truthful.

Dr Mitchell has disclosed that she has received consulting fees from Genentech Advisory Board and contracted research funding (to the university) from Lilly and Genentech. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

* Amy Furedy, RN, OCN (clinical content reviewer/planner) - no relevant financial relationships
* Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
* Christi Gray (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

1. **[URL and Mobile App Name] \*\*\*Should be discussed and decided upon at the Kickoff Meeting.**

www.primeoncology.org/2014primeroundcrc\_webcast

Page Title

Primary Keyword | Secondary Keyword

Insert Mobile App Name (restricted to 23 characters, including spaces. Conference names and abbreviations [ie, ASCO, ISHL] are appropriate to use. Do not include the location or year in the title. For Web activities, it is not necessary to include the type of activity [ie, CSP, Expert Review] in the title, as this will be indicated below the title. For Webcasts, use the same app title as was used for the live activity): **prIME Rounds: CRC**

Meta Description

This CME-certified prIME Rounds Webcast focuses on optimal treatment selection and sequence for patients with progressive metastatic colorectal cancer.

Key Words/Key Phrases

mCRC

EGFR

VEGF

Bevacizumab

KRAS mutation

RAS mutation

Cetuximab

Panitumumab

VEGF trap

Aflibercept

Ziv-aflibercept

Ramucirumab

Regorafenib

TAS-102

CORRECT trial

TML trial

VELOUR trial

Edith Mitchell

Christopher Lieu

1. **[Subject Line for Email Blast]**

New prIME Rounds Webcast: Metastatic Colorectal Cancer

1. **[Email Blast Copy]**

Either list parts above that are to be included in the email blast or insert new (different) copy that is to be used in the email blast.

Example:

Title

Date/Time

Faculty

Topics

Target Audience

Learning Objectives

Continuing Education Statement

Credit Designation Statement

Disclosures

Providership (with logos)

Support (with no logos)

Fee Statement